Author

V. Noel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:bacteria (other)· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:comparative / phylogenetic analysis· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:phylogenetics / evolution· 1

Frequent Co-Authors

A. Jex· 1 shared A. M. Floriano· 1 shared A. M. Palomar· 1 shared A. Vijay· 1 shared B. L. Makepeace· 1 shared C. S. Fonseca· 1 shared D. Sassera· 1 shared E. Cararo-Lopes· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperEvolutionary Biology

A. Jex

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The origin and evolution of mitochondrial tropism in Midichloria bacteria

A. M. Floriano, G. Batisti Biffignandi, M. Castelli, E. Olivieri, E. Clementi, F. Comandatore, L. Rinaldi, M. Opara, O. Plantard, A. M. Palomar, V. Noel, A. Vijay, N. Lo, B. L. Makepeace, O. Duron, , D. Sassera

This study analyzes mitochondrial tropism in three additional Midichloria species and sequences nine novel genomes, revealing non-monophyletic patterns and genomic signatures associated with mitochondrial colonization.

bioRxiv · May 16, 2022 · PreprintEvolutionary Biology

Fibroblast Growth Factor 2 lethally sensitizes cancer cells to stress-targeted therapeutic inhibitors

M. H. Dias, C. S. Fonseca, J. D. Zeidler, L. L. Albuquerque, M. S. da Silva, E. Cararo-Lopes, M. S. Reis, V. Noel, I. A. Prior, H. A. Armelin

This study shows that FGF2 sensitizes cancer cells to stress-targeted therapies by disrupting homeostasis and inducing synthetic lethal interactions with proteasome or DNA damage inhibitors.

Molecular Oncology · Dec 3, 2018Peer-reviewedCancer Biology